市場調査レポート
商品コード
1490320

スーパージェネリック医薬品市場:業界動向と世界の予測(~2035年):治療領域別、投与経路別、分子タイプ別、低分子タイプ別、製品タイプ別、および主要な地理的地域

Super Generics Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Therapeutic Area, Route of Administration, Type of Molecule, Type of Small Molecule, Type of Product and Key Geographical Regions

出版日: | 発行: Roots Analysis | ページ情報: 英文 257 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
スーパージェネリック医薬品市場:業界動向と世界の予測(~2035年):治療領域別、投与経路別、分子タイプ別、低分子タイプ別、製品タイプ別、および主要な地理的地域
出版日: 2024年03月20日
発行: Roots Analysis
ページ情報: 英文 257 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

スーパージェネリック医薬品市場は2024年に840億米ドルとなり、2024年~2035年の予測期間中に8%のCAGRで拡大すると予測されています。

医薬品領域では、スーパージェネリック医薬品は、特許の独占権を失った先発医薬品の改良版を意味します。これらの洗練された薬理学的介入は、しばしば複合ジェネリック医薬品または付加価値ジェネリック医薬品と呼ばれ、ブランド医薬品に代わるジェネリック医薬品として機能します。注目すべきは、2022年に米国FDAが32,000以上のジェネリック医薬品を認可したことであり、米国の処方箋の91%がジェネリック医薬品で満たされています。これらの改良型スーパージェネリックには、ドラッグデリバリー、製造プロセス、再製剤技術の進歩の可能性が秘められています。この付加価値セグメントは、継続的な技術革新の枠組みの中で運営されており、医薬品市場に有望な機会を提供しています。スーパージェネリック医薬品は、通常3~7年間の独占販売権を付与されるため、開発企業は従来のジェネリック医薬品に比べて比較的高い利益率を達成することができます。FDA(米国)やEMA(欧州)などの規制機関は、これらの医薬品を精査し、スーパージェネリック医薬品市場への参入を承認します。

スーパージェネリック医薬品の開発には、安全性、有効性、品質を確保するための厳格な研究開発が必要です。業界の利害関係者は、基準先発医薬品との生物学的同等性や治療上の同等性を確立するために、大規模な前臨床試験や臨床試験に投資しています。世界中の規制当局がより多くのジェネリック医薬品を承認するにつれ、業界の競合は激化すると予想されます。この競争激化の主な結果は、ジェネリック医薬品のコストが低下し、開発企業の利益率が低下することです。そのため、特許切れ医薬品市場の成長を維持するため、企業は革新的な医薬品改変技術を徐々に採用し、より商業的見通しの高い付加価値の高い医薬品を生み出しています。小売薬局やオンライン薬局は、ジェネリック医薬品の選択肢を幅広く提供し、消費者のヘルスケア費用を削減しています。さらに、欧州の多くの国々では、ヘルスケアプロバイダーによる特別な指定がない限り、薬剤師はブランド名の処方箋をジェネリック医薬品に置き換える権限を持っています。

当レポートでは、世界のスーパージェネリック医薬品市場について調査し、市場の概要とともに、治療領域別、投与経路別、分子タイプ別、低分子タイプ別、製品タイプ別、主要地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 調査手法

第3章 経済およびその他のプロジェクト特有の考慮事項

第4章 エグゼクティブサマリー

第5章 イントロダクション

第6章 スーパージェネリック医薬品:市場情勢

  • 章の概要
  • スーパージェネリック医薬品:市場情勢

第7章 スーパージェネリック技術:市場情勢

  • 章の概要
  • スーパージェネリック技術:市場情勢
  • スーパージェネリック技術開発者

第8章 技術競合分析

  • 章の概要
  • 調査手法と主要パラメータ
  • 北米に拠点を置く企業が提供する技術
  • 欧州に拠点を置く企業が提供する技術
  • アジア太平洋に拠点を置く企業が提供する技術

第9章 企業プロファイル

  • 章の概要
  • Ascendia Pharmaceuticals
  • CritiTech
  • Crossject
  • DelSiTech
  • Heron Therapeutics
  • Latitude Pharmaceuticals
  • Mayne Pharma
  • Neurelis
  • Rubicon Research
  • Taiwan Liposome Company
  • tesa Labtec

第10章 ケーススタディ:承認済みスーパージェネリック医薬品

  • 章の概要
  • オーステド(R)
  • アブラキサン(R)
  • アビカス(R)
  • プロシスビ(R)
  • トロケンディXR(R)

第11章 スーパージェネリック医薬品:有望な医薬品候補

  • 章の概要
  • 上市済み医薬品候補

第12章 SWOT分析

第13章 世界のスーパージェネリック医薬品市場

  • 章の概要
  • 主な前提と調査手法
  • スーパージェネリック医薬品市場全体、過去の動向(2018年~2022年)および予測推定(2023年~2035年)
  • スーパージェネリック医薬品市場:治療領域別、2023年~2035年
  • スーパージェネリック医薬品市場:投与経路別、2023年~2035年
  • スーパージェネリック医薬品市場:分子タイプ別、2023年~2035年
  • スーパージェネリック医薬品市場:低分子タイプ別、2023年~2035年
  • スーパージェネリック医薬品市場:製品タイプ別、2023年~2035年
  • スーパージェネリック医薬品市場:地域別、2023年~2035年

第14章 結論

第15章 付録1:表形式データ

第16章 付録II:企業および団体一覧

図表

List of Tables

  • Table 5.1 Different Nomenclatures Used for Value-added Generics
  • Table 5.2 Comparison of FDA Drug Approval Pathways
  • Table 5.3 Market Exclusivity Period for Different Submission Classifications
  • Table 5.4 Comparison of Drug Development Timeline
  • Table 6.1 Super Generic Drugs: List of FDA Approved Drugs, 2016-2024
  • Table 6.2 Super Generic Drugs: Additional Details, 2016-2024
  • Table 7.1 Super Generic Technologies: Information on Type of Drug Modification and Type of Technology
  • Table 7.2 Super Generic Technologies: Information on Type of Molecule, Route of Administration and Type of Value Addition
  • Table 7.3 Super Generic Technologies: List of Developers
  • Table 9.1 List of Profiled Supergeneric Technology Providers
  • Table 9.2 CritiTech (NanOlogy): Pipeline Overview
  • Table 9.3 CritiTech (NanOlogy): Recent Developments and Future Outlook
  • Table 9.4 Crossject: Pipeline Overview
  • Table 9.5 Crossject: Recent Developments and Future Outlook
  • Table 9.6 DelSiTech: Pipeline Overview
  • Table 9.7 DelSiTech: Recent Developments and Future Outlook
  • Table 9.8 Heron Therapeutics: Recent Developments and Future Outlook
  • Table 9.11 Mayne Pharma: Recent Developments and Future Outlook
  • Table 9.12 Neurelis: Pipeline Overview
  • Table 9.13 Taiwan Liposome Company: Pipeline Overview
  • Table 9.14 Taiwan Liposome Company: Recent Developments and Future Outlook
  • Table 10.1 Adverse Events Comparison: Austedo(R) versus Xenazine(R)
  • Table 10.2 Adverse Events Comparison: Abraxane(R) versus Taxol(R)
  • Table 10.3 Adverse Events Comparison: Procysbi(R) versus Cystagon(R)
  • Table 10.4 Adverse Events Comparison: Trokendi XR(R) versus Topiramate IR(R)
  • Table 11.1 Most Likely Candidates for Supergeneric Development
  • Table 11.2 Likely Candidates for Supergeneric Development
  • Table 11.3 Less Likely Candidates for Supergeneric Development
  • Table 11.4 Least Likely Candidates for Supergeneric Development
  • Table 15.1 Impact of Number of Drug Manufacturers on Price of Generic Drugs
  • Table 15.5 Historical Drug Development Costs
  • Table 15.6 Super Generic Drugs: Distribution by Route of Administration
  • Table 15.7 Super Generic Drugs: Distribution by Target Indication
  • Table 15.8 Super Generic Drugs: Distribution by Target Therapeutic Area
  • Table 15.9 Super Generic Drugs: Distribution by Submission Classification Code
  • Table 15.10 Most Active Players: Analysis by Number of Super Generic Drugs
  • Table 15.11 Super Generic Technologies: Distribution by Type of Drug Modification
  • Table 15.12 Super Generic Technologies: Distribution by Type of Technology
  • Table 15.13 Super Generic Technologies: Distribution by Type of Molecules
  • Table 15.14 Super Generic Technologies: Distribution by Route of Administration
  • Table 15.15 Super Generic Technologies: Distribution by Type of Value Addition
  • Table 15.16 Super Generic Technology Developers: Distribution by Year of Establishment
  • Table 15.17 Super Generic Technology Developers: Distribution by Company Size
  • Table 15.18 Super Generic Technology Developers: Distribution by Location of Headquarters (Region)
  • Table 15.20 Most Active Players: Distribution by Number of Super Generic Technologies
  • Table 15.26 Mayne Pharma: Annual Revenues, FY 2019- HI FY 2024 (USD Million)
  • Table 15.27 Taiwan Liposome Company: Annual Revenues, 2014-H1 2019 (NT$ Million)
  • Table 15.28 Revenue Comparison: Xenazine(R) versus Austedo(R) (USD Million)
  • Table 15.29 Annual Revenues: Abraxane(R) 2012-2018 (USD Million)
  • Table 15.30 Annual Revenues: Avycaz(R) 2015-2018 (USD Million)
  • Table 15.31 Annual Revenues: Procysbi(R) 2016-2018 (USD Million)
  • Table 15.32 Annual Revenues: Trokendi XR(R) 2013-2018 (USD Million)
  • Table 15.33 Supergeneric Drugs Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035): Base Scenario (USD Billion)
  • Table 15.34 Super Generics Market: Distribution by Therapeutic Area, 2023 and 2035 (USD Billion)
  • Table 15.35 Super Generics Market: Distribution by Route of Administration, 2023 and 2035 (USD Billion)
  • Table 15.36 Super Generics Market: Distribution by Type of Molecule, 2023 and 2035 (USD Billion)
  • Table 15.37 Super Generics Market: Distribution by Type of Small Molecule, 2023 and 2035 (USD Billion)
  • Table 15.38 Super Generics Market: Distribution by Type of Product, 2023 and 2035 (USD Billion)
  • Table 15.39 Super Generics Market: Distribution by Geography, 2023 and 2035 (USD Billion)
  • Figure 15.40 Supergeneric Drugs Market in North America, 2023-2035 (USD Billion)
  • Table 15.41 Super Generics Market for Oncological Disorders in North America, 2023-2035 (USD Billion)
  • Table 15.42 Super Generics Market for Metabolic Disorders in North America, 2023-2035 (USD Billion)
  • Table 15.43 Super Generics Market for Neurological Disorders in North America, 2023-2035 (USD Billion)
  • Table 15.44 Super Generics Market for Respiratory Disorders in North America, 2023-2035 (USD Billion) (USD Billion)
  • Table 15.45 Super Generics Market for Cardiovascular Disorders in North America, 2023-2035 (USD Billion)
  • Table 15.46 Super Generics Market for Other Disorders in North America, 2023-2035 (USD Billion)
  • Table 15.47 Super Generics Market for Oral Route of Administration in North America, 2023-2035 (USD Billion)
  • Table 15.48 Super Generics Market for Subcutaneous Route of Administration in North America, 2023-2035 (USD Billion)
  • Table 15.49 Super Generics Market for Intravenous Route of Administration in North America, 2023-2035 (USD Billion)
  • Table 15.50 Super Generics Market for Other Routes of Administration in North America, 2023-2035 (USD Billion)
  • Table 15.51 Super Generics Market for Small Molecule in North America, 2023-2035 (USD Billion)
  • Table 15.52 Super Generics Market for Biologics in North America, 2023-2035 (USD Billion)
  • Table 15.53 Super Generics Market for Complex Generics in North America, 2023-2035 (USD Billion)
  • Table 15.54 Super Generics Market for Other Small Molecules in North America, 2023-2035 (USD Billion)
  • Table 15.55 Super Generics Market for Prefilled Syringe in North America, 2023-2035 (USD Billion)
  • Table 15.56 Super Generics Market for Vials in North America, 2023-2035 (USD Billion)
  • Table 15.57 Super Generics Market for Aerosols in North America, 2023-2035 (USD Billion)
  • Table 15.58 Super Generics Market for Tablets in North America, 2023-2035 (USD Billion)
  • Table 15.59 Super Generics Market for Capsules in North America, 2023-2035 (USD Billion)
  • Table 15.60 Super Generics Market for Other Type of Products in North America, 2023-2035 (USD Billion)
  • Table 15.61 Supergeneric Drugs Market in Europe, 2023-2035 (USD Billion)
  • Table 15.62 Super Generics Market for Oncological Disorders in Europe, 2023-2035 (USD Billion)
  • Table 15.63 Super Generics Market for Metabolic Disorders in Europe, 2023-2035 (USD Billion)
  • Table 15.64 Super Generics Market for Neurological Disorders in Europe, 2023-2035 (USD Billion)
  • Table 15.65 Super Generics Market for Respiratory Disorders in Europe, 2023-2035 (USD Billion)
  • Table 15.66 Super Generics Market for Cardiovascular Disorders in Europe, 2023-2035 (USD Billion)
  • Table 15.67 Super Generics Market for Other Disorders in Europe, 2023-2035 (USD Billion)
  • Table 15.68 Super Generics Market for Oral Route of Administration in Europe, 2023-2035 (USD Billion)
  • Table 15.69 Super Generics Market for Subcutaneous Route of Administration in Europe, 2023-2035 (USD Billion)
  • Table 15.70 Super Generics Market for Intravenous Route of Administration in Europe, 2023-2035 (USD Billion)
  • Table 15.71 Super Generics Market for Other Routes of Administration in Europe, 2023-2035 (USD Billion)
  • Table 15.72 Super Generics Market for Small Molecule in Europe, 2023-2035 (USD Billion)
  • Table 15.73 Super Generics Market for Biologics in Europe, 2023-2035 (USD Billion)
  • Table 15.74 Super Generics Market for Complex Generics in Europe, 2023-2035 (USD Billion)
  • Table 15.75 Super Generics Market for Other Small Molecules in Europe, 2023-2035 (USD Billion)
  • Table 15.76 Super Generics Market for Prefilled Syringe in Europe, 2023-2035 (USD Billion)
  • Table 15.77 Super Generics Market for Vials in Europe, 2023-2035 (USD Billion)
  • Table 15.78 Super Generics Market for Aerosols in Europe, 2023-2035 (USD Billion)
  • Table 15.79 Super Generics Market for Tablets in Europe, 2023-2035 (USD Billion)
  • Table 15.80 Super Generics Market for Capsules in Europe, 2023-2035 (USD Billion)
  • Table 15.81 Super Generics Market for Other Type of Products in Europe, 2023-2035 (USD Billion)
  • Table 15.82 Supergeneric Drugs Market in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.83 Super Generics Market for Oncological Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.84 Super Generics Market for Metabolic Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.85 Super Generics Market for Neurological Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.86 Super Generics Market for Respiratory Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.87 Super Generics Market for Cardiovascular Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.88 Super Generics Market for Other Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.89 Super Generics Market for Oral Route of Administration in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.90 Super Generics Market for Subcutaneous Route of Administration in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.91 Super Generics Market for Intravenous Route of Administration in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.92 Super Generics Market for Other Routes of Administration in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.93 Super Generics Market for Small Molecule in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.94 Super Generics Market for Biologics in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.95 Super Generics Market for Complex Generics in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.96 Super Generics Market for Other Small Molecules in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.97 Super Generics Market for Prefilled Syringe in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.98 Super Generics Market for Vials in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.99 Super Generics Market for Aerosols in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.100 Super Generics Market for Tablets in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.101 Super Generics Market for Capsules in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.102 Super Generics Market for Other Type of Products in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.103 Supergeneric Drugs Market in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.104 Super Generics Market for Oncological Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.105 Super Generics Market for Metabolic Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.106 Super Generics Market for Neurological Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.107 Super Generics Market for Respiratory Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.108 Super Generics Market for Cardiovascular Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.109 Super Generics Market for Other Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.110 Super Generics Market for Oral Route of Administration in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.111 Super Generics Market for Subcutaneous Route of Administration in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.112 Super Generics Market for Intravenous Route of Administration in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.113 Super Generics Market for Other Routes of Administration in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.114 Super Generics Market for Small Molecule in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.115 Super Generics Market for Biologics in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.116 Super Generics Market for Complex Generics in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.117 Super Generics Market for Other Small Molecules in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.118 Super Generics Market for Prefilled Syringe in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.119 Super Generics Market for Vials in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.120 Super Generics Market for Aerosols in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.121 Super Generics Market for Tablets in Rest of the World, 2023-2035 (USD Billion)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Forecast Methodology
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 2.4 Research Methodology: Key Market Segmentation
  • Figure 3.1 Lessons Learnt from Past Recessions
  • Figure 5.1 Impact of Number of Drug Manufacturers on Price of Generic Drugs
  • Figure 5.2 Advantages Offered by Super Generics
  • Figure 5.3 Historical Drug Development Costs
  • Figure 6.1 Super Generic Drugs: Distribution by Route of Administration
  • Figure 6.2 Super Generic Drugs: Distribution by Target Indication
  • Figure 6.3 Super Generic Drugs: Distribution by Target Therapeutic Area
  • Figure 6.4 Super Generic Drugs: Distribution by Submission Classification Code
  • Figure 6.5 Most Active Players: Distribution by Number of Super Generic Drugs
  • Figure 7.1 Super Generic Technologies: Distribution by Type of Drug Modification
  • Figure 7.2 Super Generic Technologies: Distribution by Type of Technology
  • Figure 7.3 Super Generic Technologies: Distribution by Type of Molecules
  • Figure 7.4 Super Generic Technologies: Distribution by Route of Administration
  • Figure 7.5 Super Generic Technologies: Distribution by Type of Value Addition
  • Figure 7.6 Super Generic Technology Providers: Distribution by Year of Establishment
  • Figure 7.7 Super Generic Technology Providers: Distribution by Company Size
  • Figure 7.8. Super Generic Technology Providers: Distribution by Location of Headquarters (Region)
  • Figure 7.9. Most Active Players: Distribution by Number of Super Generic Technologies
  • Figure 8.1 Technology Competitiveness Analysis: Technologies Offered by Companies based in North America (Peer Group I)
  • Figure 8.2 Technology Competitiveness Analysis: Technologies Offered by Companies based in North America (Peer Group II)
  • Figure 8.3 Technology Competitiveness Analysis: Technologies Offered by Companies based in Europe
  • Figure 8.4 Technology Competitiveness Analysis: Technologies Offered by Companies based in Asia-Pacific
  • Figure 9.1 Ascendia Pharmaceuticals: Technology Portfolio
  • Figure 9.2 CritiTech: Technology Portfolio
  • Figure 9.3 Intellipharmaceutics International: Annual Revenues, 2013- H1 2019 (USD Million)
  • Figure 9.6 LATITUDE Pharmaceuticals: Technology Portfolio
  • Figure 9.7 Mayne Pharma: Annual Revenues, FY 2019-HI FY 2024 (USD Million)
  • Figure 9.8 Mayne Pharma: Technology Portfolio
  • Figure 9.9 Rubicon Research: Technology Portfolio
  • Figure 9.10 Taiwan Liposome Company: Annual Revenues, 2014-H1 2019 (NT$ Million)
  • Figure 9.11 Taiwan Liposome Company: Technology Portfolio
  • Figure 9.12 tesa Labtec: Technology Portfolio
  • Figure 10.1 Austedo(R): Development Timeline
  • Figure 10.2 Revenue Comparison: Xenazine(R) versus Austedo(R) (USD Million)
  • Figure 10.3 Abraxane(R): Development Timeline
  • Figure 10.4 Revenue Comparison: Taxol(R) versus Abraxane(R) (USD Million)
  • Figure 10.5 Annual Revenues: Abraxane(R) 2012-2018 (USD Million)
  • Figure 10.6 Avycaz(R): Development Timeline
  • Figure 10.7 Annual Revenues: Avycaz(R) 2015-2018 (USD Million)
  • Figure 10.8 Procysbi(R): Development Timeline
  • Figure 10.9 Annual Revenues: Procysbi(R) 2016-2018 (USD Million)
  • Figure 10.10 Trokendi XR(R): Development Timeline
  • Figure 10.11 Annual Revenues: Trokendi XR(R) 2013-2018 (USD Million)
  • Figure 12.1 Super Generics: SWOT Analysis
  • Figure 12.2 Comparison of SWOT Factors: Harvey Ball Analysis
  • Figure 13.1 Supergeneric Drugs Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035): Base Scenario (USD Billion)
  • Figure 13.2 Super Generics Market: Distribution by Therapeutic Area, 2023 and 2035 (USD Billion)
  • Figure 13.3 Super Generics Market: Distribution by Route of Administration, 2023 and 2035 (USD Billion)
  • Figure 13.4 Super Generics Market: Distribution by Type of Molecule, 2023 and 2035 (USD Billion)
  • Figure 13.5 Super Generics Market: Distribution by Type of Small Molecule, 2023 and 2035 (USD Billion)
  • Figure 13.6 Super Generics Market: Distribution by Type of Product, 2023 and 2035 (USD Billion)
  • Figure 13.7 Super Generics Market: Distribution by Geography, 2023 and 2035 (USD Billion)
  • Figure 13.8 Supergeneric Drugs Market in North America, 2023-2035 (USD Billion)
  • Figure 13.9 Super Generics Market for Oncological Disorders in North America, 2023-2035 (USD Billion)
  • Figure 13.10 Super Generics Market for Metabolic Disorders in North America, 2023-2035 (USD Billion)
  • Figure 13.11 Super Generics Market for Neurological Disorders in North America, 2023-2035 (USD Billion)
  • Figure 13.12 Super Generics Market for Respiratory Disorders in North America, 2023-2035 (USD Billion) (USD Billion)
  • Figure 13.13 Super Generics Market for Cardiovascular Disorders in North America, 2023-2035 (USD Billion)
  • Figure 13.14 Super Generics Market for Other Disorders in North America, 2023-2035 (USD Billion)
  • Figure 13.15 Super Generics Market for Oral Route of Administration in North America, 2023-2035 (USD Billion)
  • Figure 13.16 Super Generics Market for Subcutaneous Route of Administration in North America, 2023-2035 (USD Billion)
  • Figure 13.17 Super Generics Market for Intravenous Route of Administration in North America, 2023-2035 (USD Billion)
  • Figure 13.18 Super Generics Market for Other Routes of Administration in North America, 2023-2035 (USD Billion)
  • Figure 13.19 Super Generics Market for Small Molecule in North America, 2023-2035 (USD Billion)
  • Figure 13.20 Super Generics Market for Biologics in North America, 2023-2035 (USD Billion)
  • Figure 13.21 Super Generics Market for Complex Generics in North America, 2023-2035 (USD Billion)
  • Figure 13.22 Super Generics Market for Other Small Molecules in North America, 2023-2035 (USD Billion)
  • Figure 13.23 Super Generics Market for Prefilled Syringe in North America, 2023-2035 (USD Billion)
  • Figure 13.24 Super Generics Market for Vials in North America, 2023-2035 (USD Billion)
  • Figure 13.25 Super Generics Market for Aerosols in North America, 2023-2035 (USD Billion)
  • Figure 13.26 Super Generics Market for Tablets in North America, 2023-2035 (USD Billion)
  • Figure 13.27 Super Generics Market for Capsules in North America, 2023-2035 (USD Billion)
  • Figure 13.28 Super Generics Market for Other Type of Products in North America, 2023-2035 (USD Billion)
  • Figure 13.29 Supergeneric Drugs Market in Europe, 2023-2035 (USD Billion)
  • Figure 13.30 Super Generics Market for Oncological Disorders in Europe, 2023-2035 (USD Billion)
  • Figure 13.31 Super Generics Market for Metabolic Disorders in Europe, 2023-2035 (USD Billion)
  • Figure 13.32 Super Generics Market for Neurological Disorders in Europe, 2023-2035 (USD Billion)
  • Figure 13.33 Super Generics Market for Respiratory Disorders in Europe, 2023-2035 (USD Billion)
  • Figure 13.34 Super Generics Market for Cardiovascular Disorders in Europe, 2023-2035 (USD Billion)
  • Figure 13.35 Super Generics Market for Other Disorders in Europe, 2023-2035 (USD Billion)
  • Figure 13.36 Super Generics Market for Oral Route of Administration in Europe, 2023-2035 (USD Billion)
  • Figure 13.37 Super Generics Market for Subcutaneous Route of Administration in Europe, 2023-2035 (USD Billion)
  • Figure 13.38 Super Generics Market for Intravenous Route of Administration in Europe, 2023-2035 (USD Billion)
  • Figure 13.39 Super Generics Market for Other Routes of Administration in Europe, 2023-2035 (USD Billion)
  • Figure 13.40 Super Generics Market for Small Molecule in Europe, 2023-2035 (USD Billion)
  • Figure 13.41 Super Generics Market for Biologics in Europe, 2023-2035 (USD Billion)
  • Figure 13.42 Super Generics Market for Complex Generics in Europe, 2023-2035 (USD Billion)
  • Figure 13.43 Super Generics Market for Other Small Molecules in Europe, 2023-2035 (USD Billion)
  • Figure 13.44 Super Generics Market for Prefilled Syringe in Europe, 2023-2035 (USD Billion)
  • Figure 13.45 Super Generics Market for Vials in Europe, 2023-2035 (USD Billion)
  • Figure 13.46 Super Generics Market for Aerosols in Europe, 2023-2035 (USD Billion)
  • Figure 13.47 Super Generics Market for Tablets in Europe, 2023-2035 (USD Billion)
  • Figure 13.48 Super Generics Market for Capsules in Europe, 2023-2035 (USD Billion)
  • Figure 13.49 Super Generics Market for Other Type of Products in Europe, 2023-2035 (USD Billion)
  • Figure 13.50 Supergeneric Drugs Market in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.51 Super Generics Market for Oncological Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.52 Super Generics Market for Metabolic Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.53 Super Generics Market for Neurological Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.54 Super Generics Market for Respiratory Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.55 Super Generics Market for Cardiovascular Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.56 Super Generics Market for Other Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.57 Super Generics Market for Oral Route of Administration in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.58 Super Generics Market for Subcutaneous Route of Administration in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.59 Super Generics Market for Intravenous Route of Administration in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.60 Super Generics Market for Other Routes of Administration in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.61 Super Generics Market for Small Molecule in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.62 Super Generics Market for Biologics in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.63 Super Generics Market for Complex Generics in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.64 Super Generics Market for Other Small Molecules in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.65 Super Generics Market for Prefilled Syringe in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.66 Super Generics Market for Vials in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.67 Super Generics Market for Aerosols in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.68 Super Generics Market for Tablets in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.69 Super Generics Market for Capsules in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.70 Super Generics Market for Other Type of Products in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.71 Supergeneric Drugs Market in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.72 Super Generics Market for Oncological Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.73 Super Generics Market for Metabolic Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.74 Super Generics Market for Neurological Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.75 Super Generics Market for Respiratory Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.76 Super Generics Market for Cardiovascular Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.77 Super Generics Market for Other Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.78 Super Generics Market for Oral Route of Administration in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.79 Super Generics Market for Subcutaneous Route of Administration in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.80 Super Generics Market for Intravenous Route of Administration in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.81 Super Generics Market for Other Routes of Administration in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.82 Super Generics Market for Small Molecule in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.83 Super Generics Market for Biologics in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.84 Super Generics Market for Complex Generics in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.85 Super Generics Market for Other Small Molecules in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.86 Super Generics Market for Prefilled Syringe in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.87 Super Generics Market for Vials in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.88 Super Generics Market for Aerosols in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.89 Super Generics Market for Tablets in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.90 Super Generics Market for Capsules in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.91 Super Generics Market for Other Type of Products in Rest of the World, 2023-2035 (USD Billion)
  • Figure 14.1 Concluding Remarks: Super Generics Drugs Market Landscape
目次
Product Code: RA100483

Super Generics Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Therapeutic Area (Cardiovascular Disorders, Metabolic Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders and Other Disorders), Route of Administration (Intravenous, Oral, Subcutaneous and Others), Type of Molecule (Small and Other Molecules), Type of Small Molecule (Generics and Other Small Molecules), Type of Product (Aerosols, Capsules, Prefilled Syringes, Tablets, Vials and Other Products) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)

The Super Generics Market is valued at USD 84 billion in 2024 growing at a CAGR of 8% during the forecast period 2024-2035.

In the pharmaceutical domain the super generic drugs represent the enhanced versions of original pharmaceuticals that have lost their patent exclusivity. These refined pharmacological interventions are often termed as complex generics or value-added generics and serve as generic alternatives to their branded counterparts. Notably, in 2022, the US FDA sanctioned over 32,000 generic drug products, with 91% of all US prescriptions being filled with generics. These improved super generics hold the potential for advancements in drug delivery, manufacturing processes, and reformulation techniques. This value-added segment operates within a framework of ongoing innovation, offering promising opportunities in the pharmaceutical market. Super generic drugs are granted a form of marketing exclusivity, typically for 3 to 7 years, allowing developers to achieve relatively high profit margins as compared to the conventional generics. Regulatory bodies such as the FDA (in the US) or the EMA (in Europe) scrutinize these drugs and grant approval for their entry in the super generics market.

Developing super generic drugs entails rigorous research and development to ensure their safety, efficacy, and quality. Industry stakeholders invest in extensive preclinical and clinical studies to establish bioequivalence or therapeutic equivalence with the reference brand-name drug. As regulatory agencies worldwide greenlight more generic drugs, competition in the industry is expected to intensify. The primary consequence of this heightened competition is a decrease in the cost of generics, leading to reduced profit margins for developers. Hence, to sustain growth in the off-patent drug market, companies are progressively adopting innovative drug alteration techniques to create value-added medicinal products with better commercial prospects. Retail and online pharmacies offer a wide array of generic options, empowering consumers to lower healthcare expenses. Moreover, in numerous European countries, pharmacists have the authority to substitute brand-name prescriptions with generic equivalents unless otherwise specified by healthcare. providers.

Key Market Segments

Therapeutic Area

  • Cardiovascular Disorders
  • Metabolic Disorders
  • Neurological Disorders
  • Oncological Disorders
  • Respiratory Disorders
  • Other Disorders

Route of Administration

  • Intravenous
  • Oral
  • Subcutaneous
  • Others

Type of Molecule

  • Small
  • Other Molecules

Type of Small Molecule

  • Generics
  • Other Small Molecule

Type of Product

  • Aerosols
  • Capsules
  • Prefilled Syringes
  • Tablets
  • Vials
  • Other Products

Geography

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Research Coverage:

  • A summary of super generics technologies, including details on various pertinent parameters such as the type of drug modification, technology type, molecules formulated/delivered, route of administration, and type of value addition. This encompasses information on technology providers offering platforms/solutions for super generic drug development, including their year of establishment, company size (in terms of the number of employees), and headquarters location.
  • An insightful analysis of the competitiveness of the technologies compiled in our database, considering pertinent parameters including supplier power (based on the company size of technology providers) and technology competitiveness, such as the type of molecule, impact on drug properties, and route of administration.
  • Detailed profiles of prominent technology developers involved in this domain are provided, offering an overview of the company, its financial information where available, technology portfolio, recent advancements, and future outlook.
  • A compilation of marketed generics that, in our assessment, are poised to be developed as super generics in the near future, derived from a thorough analysis considering various pertinent parameters. These parameters include the current annual cost of treatment of the parent drug, year of patent expiry, sales revenues generated in the year prior to patent expiry, target therapeutic area, and the number of competitor (generic) drugs available in the market.
  • Comprehensive case studies are presented for five approved supergeneric drugs, encompassing an overview of the drug along with details on the original/parent drug, the value proposition offered by the supergeneric version, pricing strategies adopted by the developer where available, annual sales revenues of the supergeneric and parent drug if available, and key learnings/takeaways from each case study.
  • A discourse on associated trends, key drivers, and challenges within a SWOT framework, which are anticipated to influence the evolution of the industry, accompanied by a Harvey ball analysis to illustrate the relative impact of each SWOT parameter on the overall super generics market.
  • A thorough assessment of the current market size, existing opportunity, and the future growth potential of the super generics market over the next decade is conducted. Drawing from various parameters, including likely adoption trends, we have formulated an informed estimate on the market evolution during the forecast period from 2024 to 2035. The report also includes an analysis of the likely distribution of current and forecasted opportunities within the super generics market. Additionally, to accommodate future uncertainties and enhance the robustness of our model, three forecast scenarios-conservative, base, and optimistic-are provided, representing different trajectories of growth in the super generics market.

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the Super Generics Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

  • Accord Healthcare
  • Alcon Laboratories
  • Ascendia Pharmaceuticals
  • Azurity Pharmaceuticals
  • Baxter
  • CritiTech
  • Crossject
  • DelSiTech
  • Dr. Reddy's Laboratories
  • Exela Pharma Sciences
  • Harrow Health
  • Heron Therapeutics
  • Hikma Pharmaceuticals
  • Intellipharmaceutics International
  • Kashiv BioSciences
  • Latitude Pharmaceuticals
  • Mayne Pharma
  • meda pharmaceuticals
  • Neurelis
  • Rubicon Research
  • Sun Pharmaceutical industries
  • Taiwan Liposome Company
  • Tesa Labtec
  • Teva Pharmaceutical

TABLE OF CONTENTS

Table Of Contents

1. PREFACE

  • 1.1 Introduction
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact / Related Factors
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Overview of Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.3. Foreign Exchange Impact
      • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Overview of Generic Drugs
    • 5.2.1. Key Challenges within the Generics Industry
      • 5.2.1.1. Policy Changes
      • 5.2.1.2. Increasing Competition
      • 5.2.1.3. Price Erosion
  • 5.3. Super Generics
    • 5.3.1. Techniques Used for the Development of Super Generics
    • 5.3.2. Regulatory Pathways for Approval of Super Generics
  • 5.4. Advantages of Super Generics
    • 5.4.1. Improved Efficacy
    • 5.4.2. Increased IP Protection
    • 5.4.3. Cost and Time Efficient Development Process
  • 5.5. Challenges Related to Super Generics
  • 5.6. Future Perspectives

6. SUPER GENERIC DRUGS: MARKET LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Super Generic Drugs: Overall Market Landscape
    • 6.2.1. Analysis by Route of Administration
    • 6.2.2. Analysis by Target Indication
    • 6.2.3. Analysis by Target Therapeutic Area
    • 6.2.4. Analysis by Submission Classification Code
    • 6.2.5. Most Active Players: Analysis by Number of Super Generic Drugs

7. SUPER GENERIC TECHNOLOGIES: MARKET LANDSCAPE

  • 7.1 Chapter Overview
  • 7.2. Super Generic Technologies: Overall Market Landscape
    • 7.2.1 Analysis by Type of Drug Modification
    • 7.2.2 Analysis by Type of Technology
    • 7.2.3 Analysis by Type of Molecules Formulated / Delivered
    • 7.2.4 Analysis by Route of Administration
    • 7.2.5 Analysis by Type of Value Addition
  • 7.3. Super Generics Technology Developers
    • 7.3.1 Analysis by Year of Establishment
    • 7.3.2 Analysis by Company Size
    • 7.3.3 Analysis by Location of Headquarters (Region)
    • 7.3.4. Most Active Players: Analysis by Number of Super Generics Technologies

8. TECHNOLOGY COMPETITIVENESS ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Methodology and Key Parameters
  • 8.3. Technologies Offered by Companies based in North America
    • 8.3.1 Technologies Offered by Companies based in North America (Peer Group I)
    • 8.3.2 Technologies Offered by Companies based in North America (Peer Group II)
  • 8.4 Technologies Offered by Companies based in Europe
  • 8.5. Technologies Offered by Companies based in Asia-Pacific

9. COMPANY PROFILES

  • 9.1. Chapter Overview
  • 9.2. Ascendia Pharmaceuticals
    • 9.2.1. Company Overview
    • 9.2.2. Technology Portfolio
      • 9.2.2.1. NanoSol
      • 9.2.2.2. AmorSol
      • 9.2.2.3. EmulSol
    • 9.2.3. Recent Developments and Future Outlook
  • 9.3. CritiTech
    • 9.3.1. Company Overview
    • 9.3.2. Technology Portfolio
      • 9.3.2.1. Spray Drying Technology
      • 9.3.2.2. Supercritical Precipitation Technology
    • 9.3.3. Recent Developments and Future Outlook
  • 9.4. Crossject
    • 9.4.1. Company Overview
    • 9.4.2. Technology Portfolio
      • 9.4.2.1. ZENEO(R)
    • 9.4.3. Recent Developments and Future Outlook
  • 9.5. DelSiTech
    • 9.5.1. Company Overview
    • 9.5.2. Technology Portfolio
      • 9.5.2.1. DelSiTech(TM) Silica
    • 9.5.3. Recent Developments and Future Outlook
  • 9.6. Heron Therapeutics
    • 9.6.1. Company Overview
    • 9.6.2. Technology Portfolio
      • 9.6.2.1. Biochronomer(R)
    • 9.6.3. Recent Developments and Future Outlook
  • 9.7. Latitude Pharmaceuticals
    • 9.7.1. Company Overview
    • 9.7.2. Technology Portfolio
      • 9.7.2.1. Nano-E(TM)
      • 9.7.2.2. PG-Depot(TM)
      • 9.7.2.3. ARTSS(TM)
      • 9.7.2.4. RFAP(TM) Matrix
      • 9.7.2.5. RTTS
      • 9.7.2.6. 24H(TM)
      • 9.7.2.7. MiniSpheres
      • 9.7.2.8. GelPatch
    • 9.7.3. Recent Developments and Future Outlook
  • 9.8. Mayne Pharma
    • 9.8.1. Company Overview
    • 9.8.2. Financial Information
    • 9.8.3. Technology Portfolio
      • 9.8.3.1. SUBA(TM)
      • 9.8.3.2. Cleantaste(TM)
      • 9.8.3.3. Pellet Technology
    • 9.8.4. Recent Developments and Future Outlooks
  • 9.9. Neurelis
    • 9.9.1. Company Overview
    • 9.9.2. Technology Portfolio
      • 9.9.2.1. Intravail(R)
      • 9.9.2.2. ProTek(R)
      • 9.9.2.3. Hydrogel(TM)
    • 9.9.3. Recent Developments and Future Outlook
  • 9.10. Rubicon Research
    • 9.10.1. Company Overview
    • 9.10.2. Technology Portfolio
      • 9.10.2.1. RubiERT(R)
      • 9.10.2.2. RubiDT(R)
      • 9.10.2.3. RubiReten(R)
      • 9.10.2.4. RubiSRL(R)
  • 9.11. Taiwan Liposome Company
    • 9.11.1. Company Overview
    • 9.11.2. Financial Information
    • 9.11.3. Technology Portfolio
      • 9.11.3.1. BioSeizer(R)
      • 9.11.3.2. NanoX(TM)
      • 9.11.3.3. Polymeric Micelle
    • 9.11.4. Recent Developments and Future Outlook
  • 9.12. tesa Labtec
    • 9.12.1. Company Overview
    • 9.12.2. Technology Portfolio
      • 9.12.2.1. Transfilm(R)
      • 9.12.2.2. Mucofilm(R)
      • 9.12.2.3. Rapidfilm(R)
    • 9.12.3. Recent Developments and Future Outlook

10 CASE STUDY: APPROVED SUPER GENERIC DRUGS

  • 10.1. Chapter Overview
  • 10.2. Austedo(R)
    • 10.2.1. Overview
    • 10.2.2. Originator Drug Overview
    • 10.2.3. Value Proposition
    • 10.2.4. Financial Information
    • 10.2.5. Key Learnings
  • 10.3. Abraxane(R)
    • 10.3.1. Overview
    • 10.3.2. Originator Drug Overview
    • 10.3.3. Value Proposition
    • 10.3.4. Financial Information
    • 10.3.5. Key Learnings
  • 10.4. Avycaz(R)
    • 10.4.1. Overview
    • 10.4.2. Originator Drug Overview
    • 10.4.3. Value Proposition
    • 10.4.4. Financial Information
    • 10.4.5. Key Learnings
  • 10.5. Procysbi(R)
    • 10.5.1. Overview
    • 10.5.2. Originator Drug Overview
    • 10.5.3. Value Proposition
    • 10.5.4. Financial Information
    • 10.5.5. Key Learnings
  • 10.6. Trokendi XR(R)
    • 10.6.1. Overview
    • 10.6.2. Originator Drug Overview
    • 10.6.3. Value Proposition
    • 10.6.4. Financial Information
    • 10.6.5. Key Learnings

11. SUPER GENERICS: LIKELY DRUG CANDIDATES

  • 11.1. Chapter Overview
  • 11.2. Marketed Drug Candidates
    • 11.2.1. Most Likely Drug Candidates for Super Generics
    • 11.2.2. Likely Drug Candidates for Super Generics
    • 11.2.3. Less Likely Drug Candidates for Super Generics
    • 11.2.4. Least Likely Drug Candidates for Super Generics

12. SWOT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Strengths
  • 12.3. Weakness
  • 12.4. Opportunities
  • 12.5. Threats
  • 12.6. Concluding Remarks

13. GLOBAL SUPER GENERICS MARKET

  • 13.1. Chapter Overview
  • 13.2. Key Assumptions and Methodology
  • 13.3. Overall Super Generics Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 13.4. Super Generics Market: Distribution by Therapeutic Area, 2023-2035
  • 13.5. Super Generics Market: Distribution by Route of Administration, 2023-2035
  • 13.6. Super Generics Market: Distribution by Type of Molecule, 2023-2035
  • 13.7. Super Generics Market: Distribution by Type of Small Molecule, 2023-2035
  • 13.8. Super Generics Market: Distribution by Type of Product, 2023-2035
  • 13.9. Super Generics Market: Distribution by Geography, 2023-2035
    • 13.9.1. Super Generics Market in North America, 2023-2035
      • 13.9.1.1. Super Generics Market in North America: Distribution by Therapeutic Area, 2023-2035
        • 13.9.1.1.1. Super Generics Market for Oncological Disorders in North America, 2023-2035
        • 13.9.1.1.2. Super Generics Market for Metabolic Disorders in North America, 2023-2035
        • 13.9.1.1.3. Super Generics Market for Neurological Disorders in North America, 2023-2035
        • 13.9.1.1.4. Super Generics Market for Respiratory Disorders in North America, 2023-2035
        • 13.9.1.1.5. Super Generics Market for Cardiovascular Disorders in North America, 2023-2035
        • 13.9.1.1.6. Super Generics Market for Other Disorders in North America, 2023-2035
      • 13.9.1.2. Super Generics Market: Distribution by Route of Administration in North America
        • 13.9.1.2.1. Super Generics Market for Oral Route of Administration in North America, 2023-2035
      • 13.9.12.2. Super Generics Market for Subcutaneous Route of Administration in North America, 2023-2035
        • 13.9.1.2.3. Super Generics Market for Intravenous Route of Administration in North America, 2023-2035
        • 13.9.1.2.4. Super Generics Market for Other Routes of Administration in North America, 2023-2035
      • 13.9.1.3. Super Generics Market: Distribution by Type of Molecule in North America
        • 13.9.1.3.1. Super Generics Market for Small Molecule in North America, 2023-2035
        • 13.9.1.3.2. Super Generics Market for Biologics in North America, 2023-2035
      • 13.9.1.4. Super Generics Market: Distribution by Type of Small Molecules in North America
        • 13.9.1.4.1 Super Generics Market for Complex Generics in North America, 2023-2035
        • 13.9.1.4.2. Super Generics Market for Other Small Molecules in North America, 2023-2035
      • 13.9.1.5. Super Generics Market: Distribution by Type of Product Offered in North America
        • 13.9.1.5.1. Super Generics Market for Prefilled Syringe in North America, 2023-2035
        • 13.9.1.5.2. Super Generics Market for Vials in North America, 2023-2035
        • 13.9.1.5.3. Super Generics Market for Aerosols in North America, 2023-2035
        • 13.9.1.5.4. Super Generics Market for Tablets in North America, 2023-2035
        • 13.9.1.5.5. Super Generics Market for Capsules in North America, 2023-2035
        • 13.9.1.5.6. Super Generics Market for Other Types of Products in North America, 2023-2035
    • 13.9.2. Super Generics Market in Europe, 2023-2035
      • 13.9.2.1. Super Generics Market in Europe: Distribution by Therapeutic Area, 2023-2035
        • 13.9.2.1.1. Super Generics Market for Oncological Disorders in Europe, 2023-2035
        • 13.9.2.1.2. Super Generics Market for Metabolic Disorders in Europe, 2023-2035
        • 13.9.2.1.3. Super Generics Market for Neurological Disorders in Europe, 2023-2035
        • 13.9.2.1.4. Super Generics Market for Respiratory Disorders in Europe, 2023-2035
        • 13.9.2.1.5. Super Generics Market for Cardiovascular Disorders in Europe, 2023-2035
        • 13.9.2.1.6. Super Generics Market for Other Disorders in Europe, 2023-2035
      • 13.9.2.2. Super Generics Market Distribution by Route of Administration in Europe
        • 13.9.2.2.1. Super Generics Market for Oral Route of Administration in Europe, 2023-2035
        • 13.9.2.2.2. Super Generics Market for Subcutaneous Route of Administration in Europe, 2023-2035
        • 13.9.2.2.3. Super Generics Market for Intravenous Route of Administration in Europe, 2023-2035
        • 13.9.2.2.4. Super Generics Market for Other Routes of Administration in Europe, 2023-2035
      • 13.9.2.3. Super Generic Drugs Market: Distribution by Type of Molecule in Europe
        • 13.9.2.3.1. Super Generic Drugs Market for Small Molecule in Europe, 2023-2035
        • 13.9.2.3.2. Super Generic Drugs Market for Biologics in Europe, 2023-2035
      • 13.9.2.4. Super Generic Drugs Market: Distribution by Type of Small Molecules in Europe
        • 13.9.2.4.1 Super Generic Drugs Market for Complex Generics in Europe, 2023-2035
        • 13.9.2.4.2. Super Generics Market for Other Small Molecules in Europe, 2023-2035
      • 13.9.2.5. Super Generic Market: Distribution by Type of Product Offered in Europe
        • 13.9.2.5.1. Super Generic Market for Prefilled Syringe in Europe, 2023-2035
        • 13.9.2.5.2. Super Generic Market for Vials in Europe, 2023-2035
        • 13.9.2.5.3. Super Generic Market for Aerosols in Europe, 2023-2035
        • 13.9.2.5.4. Super Generic Market for Tablets in Europe, 2023-2035
        • 13.9.2.5.5. Super Generic Market for Capsules in Europe, 2023-2035
        • 13.9.2.5.6. Super Generics Market for Other Types of Products in Europe, 2023-2035
    • 13.9.3. Super Generics Market in Asia-Pacific, 2023-2035
      • 13.9.3.1. Super Generics Market in Asia-Pacific: Distribution by Therapeutic Area, 2023-2035
        • 13.9.3.1.1. Super Generics Market for Oncological Disorders in Asia-Pacific, 2023-2035
        • 13.9.3.1.2. Super Generics Market for Metabolic Disorders in Asia-Pacific, 2023-2035
        • 13.9.3.1.3. Super Generics Market for Neurological Disorders in Asia-Pacific, 2023-2035
        • 13.9.3.1.4. Super Generics Market for Respiratory Disorders in Asia-Pacific, 2023-2035
        • 13.9.3.1.5. Super Generics Market for Cardiovascular Disorders in Asia-Pacific, 2023-2035
        • 13.9.3.1.6. Super Generics Market for Other Disorders in Asia-Pacific, 2023-2035
      • 13.9.3.2. Super Generics Market Distribution by Route of Administration in Asia-Pacific
        • 13.9.3.2.1. Super Generics Market for Oral Route of Administration in Asia-Pacific, 2023-2035
        • 13.9.3.2.2. Super Generics Market for Subcutaneous Route of Administration in Asia-Pacific, 2023-2035
        • 13.9.3.2.3. Super Generics Market for Intravenous Route of Administration in Asia-Pacific, 2023-2035
        • 13.9.4.2.4. Super Generics Market for Other Routes of Administration in Asia-Pacific, 2023-2035
      • 13.9.3.3. Super Generics Market: Distribution by Type of Molecule in Asia-Pacific
        • 13.9.3.3.1. Super Generics Market for Small Molecule in Asia-Pacific, 2023-2035
        • 13.9.3.3.2. Super Generics Market for Biologics in Asia-Pacific, 2023-2035
      • 13.9.3.4. Super Generics Market: Distribution by Type of Small Molecules in Asia-Pacific
        • 13.9.3.4.1 Super Generics Market for Complex Generics in Asia-Pacific, 2023-2035
        • 13.9.3.4.2. Super Generics Market for Other Small Molecules in Asia-Pacific, 2023-2035
      • 13.9.3.5. Super Generics Market: Distribution by Type of Product Offered in Asia-Pacific
        • 13.9.3.5.1. Super Generics Market for Prefilled Syringe in Asia-Pacific, 2023-2035
        • 13.9.3.5.2. Super Generics Market for Vials in Asia-Pacific, 2023-2035
        • 13.9.3.5.3. Super Generics Market for Aerosols in Asia-Pacific, 2023-2035
        • 13.9.3.5.4. Super Generics Market for Tablets in Asia-Pacific, 2023-2035
        • 13.9.3.5.5. Super Generics Market for Capsules in Asia-Pacific, 2023-2035
        • 13.9.3.5.6. Super Generics Market for Other Types of Products in Asia-Pacific, 2023-2035
    • 13.9.4. Super Generics Market in Rest of the World, 2023-2035
      • 13.9.4.1. Super Generics Market in Rest of the World: Distribution by Therapeutic Area, 2023-2035
        • 13.9.4.1.1. Super Generics Market for Oncological Disorders in Rest of the World, 2023-2035
        • 13.9.4.1.2. Super Generics Market for Metabolic Disorders in Rest of the World, 2023-2035
        • 13.9.4.1.3. Super Generics Market for Neurological Disorders in Rest of the World, 2023-2035
        • 13.9.4.1.4. Super Generics Market for Respiratory Disorders in Rest of the World, 2023-2035
        • 13.9.4.1.5. Super Generics Market for Cardiovascular Disorders in Rest of the World, 2023-2035
        • 13.9.4.1.6. Super Generics Market for Other Disorders in Rest of the World, 2023-2035
      • 13.9.4.2. Super Generics Market Distribution by Route of Administration in Rest of the World
        • 13.9.4.2.1. Super Generics Market for Oral Route of Administration in Rest of the World, 2023-2035
        • 13.9.4.2.2. Super Generics Market for Subcutaneous Route of Administration in Rest of the World, 2023-2035
        • 13.9.4.2.3. Super Generics Market for Intravenous Route of Administration in Rest of the World, 2023-2035
        • 13.9.4.2.4. Super Generics Market for Other Routes of Administration in Rest of the World, 2023-2035
      • 13.9.4.3. Super Generics Market: Distribution by Type of Molecule in Rest of the World
        • 13.9.4.3.1. Super Generics Market for Small Molecule in Rest of the World, 2023-2035
        • 13.9.4.3.2. Super Generics Market for Biologics in Rest of the World, 2023-2035
      • 13.9.4.4. Super Generics Market: Distribution by Type of Small Molecules in Rest of the World
        • 13.9.4.4.1 Super Generics Market for Complex Generics in Rest of the World, 2023-2035
        • 13.9.4.4.2. Super Generics Market for Other Small Molecules in Rest of the World, 2023-2035
      • 13.9.4.5. Super Generics Market: Distribution by Type of Product Offered in Rest of the World
        • 13.9.4.5.1. Super Generics Market for Prefilled Syringe in Rest of the World, 2023-2035
        • 13.9.4.5.2. Super Generics Market for Vials in Rest of the World, 2023-2035
        • 13.9.4.5.3. Super Generics Market for Aerosols in Rest of the World, 2023-2035
        • 13.9.4.5.4. Super Generics Market for Tablets in Rest of the World, 2023-2035
        • 13.9.4.5.5. Super Generics Market for Capsules in Rest of the World, 2023-2035
        • 13.9.4.5.6. Super Generics Market for Other Types of Products in Rest of the World, 2023-2035

14. CONCLUSION

15. APPENDIX 1: TABULATED DATA

16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS